Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)

Autor: Franz Mosthaf, Christoph Wyen, Markus Müller, J. M. Siehl, Marcus Hentrich, Manfred Hensel, Christian Hoffmann
Rok vydání: 2014
Předmět:
Oncology
medicine.medical_specialty
Anti-HIV Agents
Prednisolone
HIV Infections
Risk Assessment
AIDS-related lymphoma
Central Nervous System Neoplasms
Antibodies
Monoclonal
Murine-Derived
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antiretroviral Therapy
Highly Active
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Drug Interactions
B-cell lymphoma
Cyclophosphamide
Etoposide
Lymphoma
AIDS-Related
Neoplasm Staging
Performance status
business.industry
Castleman Disease
Hematopoietic Stem Cell Transplantation
virus diseases
Hematology
General Medicine
Antibiotic Prophylaxis
medicine.disease
Combined Modality Therapy
Lymphoma
Methotrexate
Private practice
Doxorubicin
Vincristine
Prednisone
Rituximab
Radiotherapy
Adjuvant
Primary effusion lymphoma
business
Diffuse large B-cell lymphoma
medicine.drug
Zdroj: Annals of hematology. 93(6)
ISSN: 1432-0584
Popis: AIDS-related aggressive B cell lymphoma (HIV-NHL) is the second most common HIV-associated malignancy. In contrast, Hodgkin-lymphoma (HL) is one of the most common non-AIDS-defining malignancies. Current evidence-based recommendations for the treatment of HIV-associated lymphoma (HIV-lymphoma) are not available. A panel of experts in the field of HIV-related lymphoma performed literature searches of the PubMed, Medline, and Cochrane databases. The consensus process was carried out as an e-mail and meeting-based discussion group. Six cycles of R-CHOP or R-EPOCH are standard of care for patients (pts) with diffuse large B cell lymphoma (DLBCL). Pts with Burkitt lymphoma and good performance status should receive dose-intensive regimens such as the GMALL B-ALL/NHL protocol. Standard therapy has not been defined for pts with plasmablastic and primary effusion lymphoma. Pts with lymphoma in sensitive relapse should receive high-dose chemotherapy followed by autologous stem cell transplantation. Stage- and risk adapted treatment yields high remission and survival rates in pts with HIV-HL similar to those achieved in HIV-negative HL pts. Combination antiretroviral therapy (cART) should be applied concurrently to chemotherapy provided that pharmacokinetic interactions are being considered. Pts with HIV-lymphoma should usually be treated in an identical manner to HIV-negative patients.
Databáze: OpenAIRE
Externí odkaz: